University of Rome Tor Vergata
uniroma2.itTotal trials
90
Active
13
Phase 3
8
Total enrollment
329,069
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 8 of 8 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Circulating tumour DNA levels assessment | — | — | — | — | — | 1 | |
| MR-proADM dosage | — | — | — | — | — | 1 | |
| Terbinafine Topical Gel | — | — | — | — | — | 1 | |
| Itraconazole 200 mg | — | — | — | — | — | 1 | |
| Terbinafine 250 mg | — | — | — | — | — | 1 | |
| Ciclopirox Topical Gel | — | — | — | — | — | 1 | |
| Amorolfine 50 MG/ML | — | — | — | — | — | 1 | |
| letermovir prophylaxis | — | — | — | — | — | 1 |
Next readouts
- 2025-07-20
- 2026-05-01
- 2027-09-30
- 2028-08-15
Top conditions
- Surgery4
- Heart Failure4
- Colon Cancer4
- Morbid Obesity3
- Breast Cancer3
- Prostate Cancer2
- Obesity, Morbid2
- Kidney Transplant; Complications2
Frequently asked questions about University of Rome Tor Vergata
- How many clinical trials does University of Rome Tor Vergata have on ClinicalTrials.gov?
- University of Rome Tor Vergata is listed as the lead sponsor on 90 clinical trials in ClinicalTrials.gov, 13 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Rome Tor Vergata's trials are in Phase 3?
- 8 of University of Rome Tor Vergata's trials are in Phase 3, spread across 8 active drug programs.
- What therapeutic areas does University of Rome Tor Vergata focus on?
- University of Rome Tor Vergata's most-studied conditions on ClinicalTrials.gov are Surgery, Heart Failure, Colon Cancer, Morbid Obesity, Breast Cancer.
- When are University of Rome Tor Vergata's next clinical trial readouts?
- University of Rome Tor Vergata has 4 upcoming primary-completion readouts tracked here; the soonest is “Mycosis Culture Collection From Dermatological Isolated”, expected around 2025-07-20.